MedPath

Ramipril

Generic Name
Ramipril
Brand Names
Altace, Altace HCT
Drug Type
Small Molecule
Chemical Formula
C23H32N2O5
CAS Number
87333-19-5
Unique Ingredient Identifier
L35JN3I7SJ

Overview

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

Background

Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.

Indication

For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.

Associated Conditions

  • Cardiovascular Events
  • Diabetic Nephropathy
  • Heart Failure
  • Hearth Failure With Reduced Ejection Fraction (HFrEF)
  • Hypertension
  • Myocardial Infarction
  • Nondiabetic proteinuric chronic kidney disease
  • Stroke
  • High risk cardiovascular event

FDA Approved Products

RAMIPRIL
Manufacturer:Atlantic Biologicals Corps
Route:ORAL
Strength:5 mg in 1 1
Approved: 2010/04/23
NDC:17856-0108
Ramipril
Manufacturer:Northwind Pharmaceuticals, LLC
Route:ORAL
Strength:2.5 mg in 1 1
Approved: 2023/12/18
NDC:51655-347
Ramipril
Manufacturer:A-S Medication Solutions
Route:ORAL
Strength:10 mg in 1 1
Approved: 2021/08/11
NDC:50090-5730
Ramipril
Manufacturer:A-S Medication Solutions
Route:ORAL
Strength:2.5 mg in 1 1
Approved: 2021/08/11
NDC:50090-5947
Ramipril
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:2.5 mg in 1 1
Approved: 2022/11/08
NDC:65862-475

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath